The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United ...

AB2 Bio has made an option and licensing agreement with Nippon Shinyaku, granting the latter the option to commercialise ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18, announced today it has entered ...

With Trump proclaiming the U.S. will recognize two sexes, male and female, there are a host of implications for trans and ...

The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...

BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...

U.S. passport offices in Minnesota are no longer allowing gender identifiers to be changed on federal travel documents, an ...

The HPRA is the national regulator across many different health products: medicines, particularly pharmaceuticals and ...

An insect-control expert has highlighted the urgent need for research and development of sustainable crop protection methods ...